TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:02
Actinium Pharmaceuticals Inc. ( ATNM ) https://www.actiniumpharma.com
4.79USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-52.29%
ATNM
SPY
30.72%
-57.31%
ATNM
SPY
112.82%
-60.55%
ATNM
SPY
201.04%
-96.99%
ATNM
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
129.61
48.84
0.16
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.65
113.30
2.97
-30.78
0.00
-0.94
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-10161.40
100.00
-11428.95
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.6402
-60.10
-63.16
0.43
Other Earnings and Cash Flow Stats:
Actinium Pharmaceuticals Inc. ( ATNM ) Net Income TTM ($MM) is -42.92
Actinium Pharmaceuticals Inc. ( ATNM ) Operating Income TTM ($MM) is -47.03
Actinium Pharmaceuticals Inc. ( ATNM ) Owners' Earnings Annual ($MM) is 0.00
Actinium Pharmaceuticals Inc. ( ATNM ) Current Price to Owners' Earnings ratio is 0.00
Actinium Pharmaceuticals Inc. ( ATNM ) EBITDA TTM ($MM) is -46.26
Actinium Pharmaceuticals Inc. ( ATNM ) EBITDA Margin is -11428.95%
Capital Allocation:
Actinium Pharmaceuticals Inc. ( ATNM ) has paid 0.00 dividends per share and bought back -1.893798 million shares in the past 12 months
Actinium Pharmaceuticals Inc. ( ATNM ) has increased its debt by 2.21 million USD in the last 12 months
Capital Structure:
Actinium Pharmaceuticals Inc. ( ATNM ) Interest-bearing Debt ($MM) as of last quarter is 2
Actinium Pharmaceuticals Inc. ( ATNM ) Annual Working Capital Investments ($MM) are -97
Actinium Pharmaceuticals Inc. ( ATNM ) Book Value ($MM) as of last quarter is 43
Actinium Pharmaceuticals Inc. ( ATNM ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
Actinium Pharmaceuticals Inc. ( ATNM ) has 82 million in cash on hand as of last quarter
Actinium Pharmaceuticals Inc. ( ATNM ) has 8 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Actinium Pharmaceuticals Inc. ( ATNM ) has 27 common shares outstanding as of last quarter
Actinium Pharmaceuticals Inc. ( ATNM ) has 0 million USD of preferred stock value
Academic Scores:
Actinium Pharmaceuticals Inc. ( ATNM ) Altman Z-Score is -4.37 as of last quarter
Actinium Pharmaceuticals Inc. ( ATNM ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Actinium Pharmaceuticals Inc. ( ATNM ) largest shareholder is owning shares at 0.00 ($MM) value
O'Loughlin Steve(Chief Financial Officer) Bought 107463 shares of Actinium Pharmaceuticals Inc. ( ATNM ) for the amount of $0.00 on 2021-09-01
2.10% of Actinium Pharmaceuticals Inc. ( ATNM ) is held by insiders, and 25.87% is held by institutions
Actinium Pharmaceuticals Inc. ( ATNM ) went public on 2012-12-27
Other Actinium Pharmaceuticals Inc. ( ATNM ) financial metrics:
FCF:-39.89
Unlevered Free Cash Flow:-176.71
EPS:-1.96
Operating Margin:-10161.40
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-121.85
Beta:0.43
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Actinium Pharmaceuticals Inc. ( ATNM ) :
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.